Hospital Mater Dei S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

The quarterly results for Hospital Mater Dei S.A. (BVMF:MATD3) were released last week, making it a good time to revisit its performance. It was not a great result overall. Although revenues beat expectations, hitting R$546m, statutory earnings missed analyst forecasts by 15%, coming in at just R$0.08 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Hospital Mater Dei after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the most recent consensus for Hospital Mater Dei from seven analysts is for revenues of R$2.15b in 2025. If met, it would imply a modest 2.4% increase on its revenue over the past 12 months. In the lead-up to this report, the analysts had been modelling revenues of R$2.25b and earnings per share (EPS) of R$0.50 in 2025. So we can see that while the consensus made a minor downgrade to revenue estimates, it no longer provides an earnings per share estimate. This suggests that the market is now more focused on revenue after the latest result.

Check out our latest analysis for Hospital Mater Dei

The average price target fell 7.8% to R$5.93, withthe analysts clearly having become less optimistic about Hospital Mater Dei'sprospects following its latest earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Hospital Mater Dei at R$8.00 per share, while the most bearish prices it at R$4.50. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Hospital Mater Dei's revenue growth is expected to slow, with the forecast 4.9% annualised growth rate until the end of 2025 being well below the historical 12% p.a. growth over the last three years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 10% per year. Factoring in the forecast slowdown in growth, it seems obvious that Hospital Mater Dei is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analysts downgraded their revenue estimates for next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Hospital Mater Dei's future valuation.

At least one of Hospital Mater Dei's seven analysts has provided estimates out to 2027, which can be seen for free on our platform here.

Even so, be aware that Hospital Mater Dei is showing 2 warning signs in our investment analysis , and 1 of those is a bit unpleasant...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.